Alexander Heinze

Alexander Heinze

Auto-generated profile, based on publicly available information

Alexander Heinze

Georg-August-Universität, Göttingen, Germany

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in European Urology
Verified
Journal Article
Closed access
FPFelix Preisser
Felix Preisser
FCFelix K.H. Chun
Felix K.H. Chun
RPRaisa S. Pompe
Raisa S. Pompe
AHAlexander Heinze
Alexander Heinze
GSGeorg Salomon
Georg Salomon
DTDerya Tilki
Derya Tilki

25 September 2019 in The Prostate
Verified
Journal Article
Closed access
PDF file
FPFelix Preisser
Felix Preisser
GCGilberto Coxilha
Gilberto Coxilha
AHAlexander Heinze
Alexander Heinze
SOSu Oh
Su Oh
FCFelix K‐H. Chun
Felix K‐H. Chun
DTDerya Tilki
Derya Tilki

28 May 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Rodrigo Suárez-IbarrolaRodrigo Suárez-Ibarrola
Rodrigo Suárez-Ibarrola
Mario Basulto-MartínezMario Basulto-Martínez
Mario Basulto-Martínez
AHAlexander Heinze
Alexander Heinze
CGChristian Gratzke
Christian Gratzke
AMArkadiusz Miernik
Arkadiusz Miernik
Radiomics texture analysis offers objective image information that could otherwise not be obtained by radiologists′ subjective radiological interpretation. We investigated radiomics applications in renal tumor assessment and provide a comprehensive review. A detailed search of original articles was performed using the PubMed-MEDLINE database until 20 March 2020 to identify English literature relevant to radiomics applications in renal tumor assessment. In total, 42 articles were included in the analysis and divided into four main categories: renal mass differentiation, nuclear grade prediction, gene expression-based molecular signatures, and patient outcome prediction. The main area of research involves accurately differentiating benign and malignant renal masses, specifically between renal cell carcinoma (RCC) subtypes and from angiomyolipoma without visible fat and oncocytoma. Nuclear grade prediction may enhance proper patient selection for risk-stratified treatment. Radiomics-predicted gene mutations may serve as surrogate biomarkers for high-risk disease, while predicting patients’ responses to targeted therapies and their outcomes will help develop personalized treatment algorithms. Studies generally reported the superiority of radiomics over expert radiological interpretation. Radiomics provides an alternative to subjective image interpretation for improving renal tumor diagnostic accuracy. Further incorporation of clinical and imaging data into radiomics algorithms will augment tumor prediction accuracy and enhance individualized medicine.

1 March 2019 in Current Opinion in Urology
Verified
Journal Article
Closed access
AHAlexander Heinze
Alexander Heinze
AGAli S. Gozen
Ali S. Gozen
JRJens Rassweiler
Jens Rassweiler
To provide a summary of surgical outcomes in percutaneous nephrolithotomy (PCNL) according to various techniques and tract sizes. Recent literature in this field concluded that standard PCNL (sPCNL) remains the optimal treatment for stones between 1 and 2.5 cm and can be managed with tracts 14–20 F, whereas small stones less than 1.5 cm can be treated with tracts under 14 F. According to new datasets, smaller tracts can be equally effective in the treatment and might offer the possibility to reduce bleeding, length of hospital stay, postoperative pain as well as overall complication rates when compared with sPCNL. On the other hand, longer operative time as well as lower stone-free rates, which have been the main drawbacks of the miniaturized approach, have recently shown to be comparable with sPCNL. At present, tract size is a highly debatable topic in percutaneous stone therapy. New systems for miniaturized PCNL have been developed to achieve comparable stone-free rates while reducing the incidence of common complications. The adoption of these techniques demands skilled surgeons and institutional investment for the acquisition of new equipment.

1 April 2020 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
SKSophie Knipper
Sophie Knipper
PKPierre I. Karakiewicz
Pierre I. Karakiewicz
AHAlexander Heinze
Alexander Heinze
FPFelix Preisser
Felix Preisser
TSThomas Steuber
Thomas Steuber
DTDerya Tilki
Derya Tilki

5 May 2020 in Urolithiasis
Verified
Journal Article
Closed access
PDF file
Mario Basulto-MartínezMario Basulto-Martínez
Mario Basulto-Martínez
DODaniel Olvera-Posada
Daniel Olvera-Posada
IVIván A. Velueta-Martínez
Iván A. Velueta-Martínez
CMCarlos Méndez-Probst
Carlos Méndez-Probst
JFJuan P. Flores-Tapia
Juan P. Flores-Tapia
AHAlexander Heinze
Alexander Heinze